白血病·淋巴瘤
白血病·淋巴瘤
백혈병·림파류
JOURNAL OF LEUKEMIA & LYMPHOMA
2010年
6期
331-333,337
,共4页
费城染色体阴性%白血病,淋巴细胞,急性%成年人%抗肿瘤联合化疗方案
費城染色體陰性%白血病,淋巴細胞,急性%成年人%抗腫瘤聯閤化療方案
비성염색체음성%백혈병,림파세포,급성%성년인%항종류연합화료방안
Philadelphia chromosome-negative%Leukemia,lymphocytic,acute%Adult%Antineoplastic combined chemotherapy protocols
目的 分析费城染色体阴性(Ph-)成年急性淋巴细胞性白血病(ALL)患者应用儿童ALL的BFM90化疗方案治疗后的远期疗效.方法 2004年8月至2007年10月,共60例Ph-成年ALL患者[中位年龄40(18~60)岁],接受BFM90方案治疗,并进行回顾性分析,其治疗结果同35例接受Hyper-CVAD方案化疗的患者[中位年龄42(18~56)岁]进行历史对照.结果 BFM90化疗42个月的完全缓解(CR)率、总生存(OS)率、无事件生存(EFS)率分别为93%(56例)、65%(39例)和60%(36例).45岁是本组年龄因素中影响预后的主要截断值.BFM90组CR、OS和EFS优于Hyper-CVAD方案历史对照组(均为P＜0.05).结论 与成年人Hyper-CVAD方案相比,儿童ALL的BFM90化疗方案治疗成年人ALL有更好的疗效.
目的 分析費城染色體陰性(Ph-)成年急性淋巴細胞性白血病(ALL)患者應用兒童ALL的BFM90化療方案治療後的遠期療效.方法 2004年8月至2007年10月,共60例Ph-成年ALL患者[中位年齡40(18~60)歲],接受BFM90方案治療,併進行迴顧性分析,其治療結果同35例接受Hyper-CVAD方案化療的患者[中位年齡42(18~56)歲]進行歷史對照.結果 BFM90化療42箇月的完全緩解(CR)率、總生存(OS)率、無事件生存(EFS)率分彆為93%(56例)、65%(39例)和60%(36例).45歲是本組年齡因素中影響預後的主要截斷值.BFM90組CR、OS和EFS優于Hyper-CVAD方案歷史對照組(均為P＜0.05).結論 與成年人Hyper-CVAD方案相比,兒童ALL的BFM90化療方案治療成年人ALL有更好的療效.
목적 분석비성염색체음성(Ph-)성년급성림파세포성백혈병(ALL)환자응용인동ALL적BFM90화료방안치료후적원기료효.방법 2004년8월지2007년10월,공60례Ph-성년ALL환자[중위년령40(18~60)세],접수BFM90방안치료,병진행회고성분석,기치료결과동35례접수Hyper-CVAD방안화료적환자[중위년령42(18~56)세]진행역사대조.결과 BFM90화료42개월적완전완해(CR)솔、총생존(OS)솔、무사건생존(EFS)솔분별위93%(56례)、65%(39례)화60%(36례).45세시본조년령인소중영향예후적주요절단치.BFM90조CR、OS화EFS우우Hyper-CVAD방안역사대조조(균위P＜0.05).결론 여성년인Hyper-CVAD방안상비,인동ALL적BFM90화료방안치료성년인ALL유경호적료효.
Objective To retrospectively analyze the efficacy of a pediatric treatment protocol,BFM90,in adult patients with acute lymphobiastic leukemia (ALL) up to the age of 60 years. Methods From August 2004 to October 2007,60 adult patients (median age,40 years; range,18 to 60 years) with Philadelphia chromosome-negative ALL were treated with the BFM90 protocol. Clinical effect were historically compared with that of the 35 patients (median age,42 years; range,18 to 56 years) who were treated with Hyper-CVAD protocol. Results At 42 months,complete remission (CR) rate,event-free survival (EFS) and overall survival (OS) rates were 93 % (56 patients),60 % (36 patients) and 65 % (39 patients),respectively.Age is an important prognostic factor,with 45 years of age as best cutoff. CR (P=0.02),OS (P ＜0.001),and EFS (P ＜0.001) of BFM90 were compared superiorly with that of the previous Hyper-CVAD experience.Conclusion These results suggest that pediatric protocol superior to the outcome of adult patients with Philadelphia chromosome-negative ALL.
